Table 4

Citrate synthase activity, and complex I- and II-dependent oxidative phosphorylation in PBMC and CK in plasma of CFS patients and controls before CPET1 and CPET2^&

CPET1

CPET2

Patients n = 15

Controls n = 15

Patients n = 15

Controls n = 15

Citrate synthase (CS) U/g protein

135 ± 61

132 ± 17

128 ± 20

154 ± 51

ATP synthesis via Complex I nmol/(0.5 h. mg protein)

7.1 ± 3.1

7.8 ± 2.8

6.7 ± 4.8

9.5 ± 5.7

ATP synthesis via Complex I nmol/(0.5 h. U CS)

54 ± 19

58 ± 21

54 ± 34

61 ± 26

ATP synthesis via Complex II nmol/(0.5 h. mg protein)

7.8 ± 5.0

8.2 ± 2.8

6.8 ± 4.9

8.9 ± 5.3

ATP synthesis via Complex II nmol/(0.5 h. U CS)

58 ± 22

60 ± 26

54 ± 36

58 ± 27

CK in plasma U/L

70 ± 25

83 ± 35

64 ± 22

96 ± 63

^& Data are presented as mean ± SD

There were no statistically significant differences between patients and controls at CPET1 or 2 (according to multivariate ANOVA), or between CEPT1 and 2 for patients or for controls (according to repeated measures ANOVA)

Vermeulen et al. Journal of Translational Medicine 2010 8:93   doi:10.1186/1479-5876-8-93